Standard Biotools Inc. (NASDAQ: LAB)

Standard BioTools Inc. develops and commercializes advanced life science tools that enable biomedical researchers to accelerate drug discovery and improve health outcomes. Operating in the proteomics and genomics segments of the life sciences research tools industry, the company provides instrumentation, consumables, and services designed to generate high-quality data across early discovery, translational, and clinical research. Its technologies empower scientists to explore disease mechanisms with precision, supporting therapeutic development in areas such as immunology, oncology, neuroscience, and cardiometabolic diseases. Following the divestiture of its aptamer-based proteomics business in early 2026, Standard BioTools retained its mass cytometry and microfluidics platforms, which remain central to its operations.

The company generates revenue primarily through the sale of instruments, consumables, and related services. Instruments, including mass cytometry and microfluidics systems, represent high-value, long-term investments for customers, while consumables such as reagents and microfluidic chips drive recurring revenue. Standard BioTools also collaborates with original equipment manufacturers to expand the application of its proprietary microfluidics technology into adjacent markets. Sales are made to research institutions, biopharmaceutical companies, and clinical laboratories, with a significant portion of revenue derived from international customers.

The company operates through the following technology-driven platforms.

• CyTOF: This segment leverages mass cytometry to enable high-dimensional single-cell analysis, allowing researchers to detect and quantify over 50 intracellular and extracellular markers simultaneously. Unlike traditional fluorescence-based flow cytometry, CyTOF eliminates spectral overlap by using metal-tagged antibodies and time-of-flight mass spectrometry, enhancing accuracy in immune profiling, biomarker discovery, and functional cell analysis. The platform includes instrumentation, reagents, and data analysis tools tailored for applications in immunology and oncology.

• Hyperion: The Hyperion spatial biology platform combines Imaging Mass Cytometry to map multiple protein markers across tissue samples while preserving spatial context. This technology enables researchers to study cellular interactions and tissue architecture at high resolution, supporting advancements in oncology, immunology, and neuroscience. The platform integrates instrumentation, multiplexed imaging capabilities, and bioinformatics tools to facilitate complex biological insights.

• Biomark: The Biomark X9 system delivers high-throughput genomics solutions for quantitative PCR applications, offering scalability and precision for large-scale studies. Utilizing microfluidics technology, the system reduces reagent consumption and increases throughput, making it suitable for genomic research, clinical studies, and biomarker discovery. The platform is designed to integrate seamlessly with data analysis tools to streamline workflows.

Standard BioTools competes in the highly fragmented and competitive life sciences research tools market, where product quality, innovation, and ease of integration into existing workflows are critical differentiators. Key competitors include established companies with broader product portfolios, stronger brand recognition, and larger sales forces, as well as emerging firms developing novel technologies. The company’s competitive advantages lie in its proprietary mass cytometry and microfluidics platforms, which offer superior multiplexing capabilities and precision compared to traditional fluorescence-based methods. Its focus on proteomics and genomics positions it well within high-growth segments, though it must continually demonstrate technological superiority to retain and expand its market share.

The company serves a diverse customer base, including leading academic research institutions, translational research centers, cancer centers, clinical research laboratories, and biopharmaceutical and biotechnology companies. Its products are marketed for research use only and are not intended for clinical diagnostic applications. Sales are conducted through a direct sales force in North America, Europe, and Asia-Pacific, as well as through distributors in Latin America, the Middle East, and other regions. The sales cycle is often lengthy, influenced by budget cycles and the need for extensive customer evaluations, which can extend the time from initial contact to purchase order receipt.